Skip to main content
Amphastar Pharmaceuticals, Inc. logo

Amphastar Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMPH ISIN · US03209R1032 LEI · 54930055TH0ZLSAQMJ38 US Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2017-05-08 Earnings Release
Country US United States of America
Listing US AMPH

About Amphastar Pharmaceuticals, Inc.

https://amphastar.com/

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing technically challenging medications. Its portfolio includes generic and proprietary injectable, intranasal, and inhalation products. The company specializes in complex medications such as biologics derived from living cells, proteins, and interchangeable biosimilars. Amphastar also develops innovative drug delivery systems and proprietary technological platforms for various routes of administration.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 8, 2017, by Amphastar Pharmaceuticals, Inc. It announces the issuance of a press release regarding financial results for the quarter ended March 31, 2017. The text explicitly states that the press release is furnished as an exhibit and that the information is not deemed "filed" for certain regulatory purposes. The document is short (3,490 characters) and primarily serves as an announcement of the earnings release rather than containing the financial results itself. According to the "Menu vs Meal" rule, this is an announcement of a report (the earnings release) rather than the report itself. Therefore, the correct classification is Earnings Release (ER).
2017-05-08 English
Regulatory Filings 2017
Regulatory Filings
2017-04-26 English
4
Director's Dealing
2017-04-25 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes information about the Annual Meeting of shareholders, voting instructions, nominees for election to the board, and ratification of the independent auditor. The document is titled 'PROXY STATEMENT' and contains detailed proxy solicitation materials. It is not the Annual Report itself, nor an announcement of a report publication. It is not a certification or a regulatory filing of another type. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI). The document length is about 5946 characters, which is consistent with a full proxy statement rather than a brief announcement.
2017-04-21 English
DEF 14A
Proxy Solicitation & Information Statement
2017-04-21 English
4
Director's Dealing
2017-04-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.